



INDO US
BIO-TECH LIMITED
(AN ISO CERTIFIED COMPANY)
CIN LO1122GJ2004PLC043550



Date: 30th August, 2024

To,
Department of Listing Operations
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400 001

Trading Symbol: INDOUS
Scrip Code: 541304

Dear Sir/Madam,

Sub: Intimation of In-Principle Approval for Migration of Indo Us Bio Tech Limited from BSE SME Platform to BSE Main Board and NSE Main Board.

Dear Sir / Madam,

We are pleased to inform that our Company has received in-principle approvals for migration from SME Platform of BSE to Main Board of both BSE & NSE on August 13, 2024 & August 30, 2024 respectively.

Please find the enclosed herewith a copy of the in-principle approval letters of the BSE and NSE.

Kindly take the above information on your records and oblige.

Thanking You,

For, Indo Us Bio Tech Limited

DIMPY
DIVYANGBHAI
JOSHI

Digitally signed by DIMPY
DIVYANGBHAI JOSHI
Date: 2024.08.30 18:58:15
+05'30'

Ms. DimpY Joshi
Company Secretary & Compliance Officer



LO/Migration/DG/IP/124/2024-25

August 13, 2024

The Company Secretary
Indo Us Bio-Tech Limited
309, Shanti Mall, Satadhar
Char Rasta, Opp. Navrang
Tower, Sola Road, Ahmedabad
– 380 061, Gujarat

Dear Sir/ Madam,

Re: In-Principle Approval for Migration of Indo Us Bio-Tech Limited from BSE SME Platform to BSE Mainboard

We refer to your Company's application dated March 23, 2024 for listing the equity shares on the BSE's Mainboard Trading Platform.

We are pleased to inform you that the same was considered by the Internal Regulatory Oversight and Review Group of the Exchange.

Accordingly, the Exchange is pleased to grant its in-principle approval to the Company's application for listing & trading its equity shares on the BSE Mainboard Platform. You are advised to complete the following formalities for listing of securities of the Company:

1. Letter of application for listing of shares on Main Board.
2. Information Memorandum of the Company in the format prescribed in Section 26 of the Companies Act 2013 read along with the Companies (Prospectus and Allotment of Securities) Rules, 2014 and duly certified by the Managing Director/ Company Secretary (Hard/ Soft copy in email). The Information Memorandum must be as on date of filing the listing application consequent to In-principle Approval.
3. Listing Agreement as per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
4. Latest Share holding pattern as per format provided by SEBI vide its circular no. CIR/CFD/CMD/13/2015 dated November 30, 2015, and financials as per Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
5. The company shall note that on migration from SME Platform to BSE's Main Board Trading Platform, all the provisions of SEBI (LODR) Regulations, 2015 will become applicable on the company, including but not limited to Corporate Governance (CG) provisions, on the first date of trading on Main Board
6. You are requested to pay Initial Listing Fees of Rs. 20,000/- and Annual Listing Fee for the Financial Year 2024-25 along with applicable Taxes (Please refer the Schedule of Listing Fees available on BSE website).

Kindly forward us the above-mentioned documents / information at the earliest to enable us to process the matter. You are requested to note that this approval is valid for a period of **45 days** from the date of this letter. Then after the company can apply for extensions as per the BSE checklist.

Yours faithfully,

For BSE Limited



Hardik Bhuta
Assistant General Manager



Prasad Bhide
Senior Manager

BSE - PUBLIC



National Stock Exchange Of India Limited

Ref: NSE/LIST/53

August 30, 2024

The Company Secretary
Indo Us Biotech Limited
309, Shanti Mall
Satadhar Char Rasta,
Opp. Navrang Tower,
Sola Road,
Ahmedabad-380061.

Kind Attn.: Ms. Dimpy Divyangbhai Joshi

Dear Madam,

Re: In-principle approval for Migration from SME Platform of BSE to Capital Market Segment (Main Board) of National Stock Exchange of India Limited

We are in receipt of your application regarding in-principle approval for migration of trading of 20052000 equity shares of Rs. 10/- each of the company from SME Platform of BSE to Capital Market Segment (Main Board) of National Stock Exchange of India Limited in terms of Securities and Exchange Board of India (Issue of Capital and Disclosure Requirement) Regulations, 2018.

In this regard, the Exchange is pleased to grant in-principle approval for proposed migration of trading in the equity shares of the company to Capital Market Segment (Main Board) of National Stock Exchange of India Limited.

Further, the Company shall ensure submission of financial results in accordance with Reg. 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, which inter-alia states that the listed entity shall, subsequent to the listing, submit its financial results for the quarter or the financial year immediately succeeding the period for which the financial statements have been disclosed in the offer document for the initial public offer, within the timeline specified in clause (a) or clause (d) of Regulation 33(3), as the case may be, or within 21 days from the date of its listing, whichever is later.

Kindly note that the Exchange will issue final approval for migration of trading in the equity shares of the company to Capital Market Segment (Main Board) of National Stock Exchange of India Limited on submission of listing application including equity listing agreement.

“Kindly note, this Exchange letter should not be construed as approval under any other Act /Regulation/rule/bye laws (except as referred above) for which the Company may be required to obtain approval from other department(s) of the Exchange. The Company is requested to separately take up matter with the concerned departments for approval, if any.”

Yours faithfully,
For National Stock Exchange of India Limited

Aboli Pitre
Manager

This Document is Digitally Signed

